Research Analysts Issue Forecasts for HRMY Q1 Earnings

Harmony Biosciences Holdings, Inc. (NASDAQ:HRMY) – Analysts at HC Wainwright issued their Q1 2027 earnings per share (EPS) estimates for Harmony Biosciences in a research report issued to clients and investors on Thursday, April 23rd. HC Wainwright analyst P. Trucchio forecasts that the company will post earnings of $0.90 per share for the quarter. HC Wainwright has a “Buy” rating and a $55.00 price objective on the stock. The consensus estimate for Harmony Biosciences’ current full-year earnings is $3.33 per share. HC Wainwright also issued estimates for Harmony Biosciences’ Q2 2027 earnings at $1.07 EPS.

A number of other equities research analysts have also recently commented on HRMY. Bank of America decreased their price target on Harmony Biosciences from $32.00 to $28.00 and set an “underperform” rating for the company in a research note on Wednesday, February 25th. Needham & Company LLC cut their price objective on Harmony Biosciences from $46.00 to $44.00 and set a “buy” rating on the stock in a report on Wednesday, February 25th. Deutsche Bank Aktiengesellschaft downgraded Harmony Biosciences from a “buy” rating to a “hold” rating and set a $31.00 target price for the company. in a report on Monday, February 23rd. Mizuho set a $50.00 price target on shares of Harmony Biosciences in a research report on Thursday, February 19th. Finally, Weiss Ratings reaffirmed a “hold (c)” rating on shares of Harmony Biosciences in a report on Monday, December 29th. One analyst has rated the stock with a Strong Buy rating, four have assigned a Buy rating, five have assigned a Hold rating and two have given a Sell rating to the stock. According to data from MarketBeat.com, the stock currently has a consensus rating of “Hold” and a consensus price target of $42.67.

Harmony Biosciences Stock Performance

Shares of HRMY stock opened at $32.08 on Friday. Harmony Biosciences has a 12-month low of $25.52 and a 12-month high of $40.87. The business’s fifty day simple moving average is $29.23 and its 200-day simple moving average is $32.68. The company has a current ratio of 3.60, a quick ratio of 3.58 and a debt-to-equity ratio of 0.17. The company has a market cap of $1.86 billion, a PE ratio of 11.84, a PEG ratio of 0.43 and a beta of 0.89.

Harmony Biosciences (NASDAQ:HRMY) last issued its quarterly earnings data on Tuesday, February 24th. The company reported $0.38 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $0.84 by ($0.46). Harmony Biosciences had a return on equity of 19.86% and a net margin of 18.29%.The firm had revenue of $243.78 million during the quarter, compared to analysts’ expectations of $240.04 million. During the same period in the previous year, the firm earned $0.85 EPS. The firm’s quarterly revenue was up 21.1% on a year-over-year basis.

Insiders Place Their Bets

In other Harmony Biosciences news, CFO Sandip Kapadia sold 3,746 shares of the business’s stock in a transaction that occurred on Monday, January 26th. The stock was sold at an average price of $37.15, for a total value of $139,163.90. Following the completion of the transaction, the chief financial officer directly owned 24,521 shares of the company’s stock, valued at approximately $910,955.15. The trade was a 13.25% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link. Corporate insiders own 11.00% of the company’s stock.

Institutional Trading of Harmony Biosciences

A number of institutional investors and hedge funds have recently made changes to their positions in the business. EverSource Wealth Advisors LLC lifted its position in shares of Harmony Biosciences by 589.9% during the 4th quarter. EverSource Wealth Advisors LLC now owns 752 shares of the company’s stock valued at $28,000 after buying an additional 643 shares in the last quarter. Allworth Financial LP increased its stake in shares of Harmony Biosciences by 286.7% during the fourth quarter. Allworth Financial LP now owns 812 shares of the company’s stock worth $30,000 after purchasing an additional 602 shares in the last quarter. Leonteq Securities AG acquired a new position in shares of Harmony Biosciences during the 4th quarter worth about $30,000. National Bank of Canada FI purchased a new position in Harmony Biosciences in the 3rd quarter valued at about $40,000. Finally, Clearstead Advisors LLC boosted its holdings in Harmony Biosciences by 145.9% in the 4th quarter. Clearstead Advisors LLC now owns 1,178 shares of the company’s stock worth $44,000 after buying an additional 699 shares during the last quarter. 86.23% of the stock is currently owned by hedge funds and other institutional investors.

About Harmony Biosciences

Harmony Biosciences Holdings, Inc is a commercial‐stage biopharmaceutical company focused on developing and delivering therapies for people with rare neurological and endocrine diseases. Founded in 2017 and headquartered in Plymouth Meeting, Pennsylvania, Harmony Biosciences went public in 2020 and trades on the Nasdaq under the ticker HRMY. The company’s mission centers on identifying and advancing medicines that address critical unmet needs in patient populations underserved by existing treatments.

The company’s flagship product is WAKIX (pitolisant), the first and only histamine H3 receptor antagonist/inverse agonist approved by the U.S.